Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Additional Information (Detail)

v3.23.1
Research and Development Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2021
Sep. 30, 2018
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Research And Development Collaboration Agreements [Line Items]          
Revenue from collaborative arrangement     $ 36,629,000 $ 8,486,000  
Research and development revenue recognized     33,627,000 8,486,000  
Grant          
Research And Development Collaboration Agreements [Line Items]          
Revenue from collaborative arrangement     2,800,000   $ 0
CPRIT Agreement | Cancer Prevention and Research Institute of Texas          
Research And Development Collaboration Agreements [Line Items]          
Product development grant awarded   $ 15,200,000      
CPRIT Agreement | Cancer Prevention and Research Institute of Texas | Grant          
Research And Development Collaboration Agreements [Line Items]          
Revenue from collaborative arrangement     12,400,000    
Grant Agreements | Grants Revenue Receivable          
Research And Development Collaboration Agreements [Line Items]          
Reimbursement amounts submitted in excess of amounts received are recorded as receivables     3,000,000.0 0  
Bristol Myers Squibb Collaboration Agreement          
Research And Development Collaboration Agreements [Line Items]          
Upfront payment $ 70,000,000.0        
Milestone payments receivable if option is exercised 874,500,000        
Transaction price allocated to performance obligations 70,000,000.0        
Revenue from collaborative arrangement     33,600,000   5,900,000
Research and development revenue recognized     25,800,000    
Deferred revenue, current     19,400,000   45,300,000
Deferred revenue, non-current     1,200,000   5,900,000
Bristol Myers Squibb Collaboration Agreement | Sales Milestone          
Research And Development Collaboration Agreements [Line Items]          
Milestone payments receivable if option is exercised $ 450,000,000.0        
Takeda Multi Target Agreement | Takeda Pharmaceuticals Inc          
Research And Development Collaboration Agreements [Line Items]          
Research and development revenue recognized     0 $ 2,600,000  
Deferred revenue     $ 0   $ 0